

# REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

**RECEIVED**  
SEP 4 2000  
File Information Unit

In re Application of

Application Number

08/320,157

Filed

Oct. 7, 1994

Group Art Unit

1804

Examiner

Chambers

Paper No. 8

Assistant Commissioner for Patents  
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

☒ (A) referred to in United States Patent Number 5,998,131 column 62

☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. \_\_\_\_\_, filed \_\_\_\_\_, on page \_\_\_\_\_ of paper number \_\_\_\_\_

☐ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. \_\_\_\_\_, filed \_\_\_\_\_, or

☐ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

*Chris Riley*

Signature

*Chris Riley*

Typed or printed name

9/14/00

Date

FOR PTO USE ONLY

Approved by: \_\_\_\_\_

(Initials)

Unit: \_\_\_\_\_



US005998131A

# United States Patent [19]

Barr et al.

[11] Patent Number: **5,998,131**  
 [45] Date of Patent: **Dec. 7, 1999**

[54] **SCREENING METHODS FOR THE IDENTIFICATION OF COMPOUNDS CAPABLE OF ABROGATING BAK-BHRF-1 PROTEIN INTERACTIONS**

[75] Inventors: **Philip J. Barr, Berkeley; Michael C. Klefer, Clayton, both of Calif.**

[73] Assignee: **LXR Biotechnology, Inc., Richmond, Calif.**

[21] Appl. No.: **08/944,530**

[22] Filed: **Oct. 7, 1997**

## Related U.S. Application Data

[62] Continuation of application No. 08/426,529, Apr. 20, 1995, abandoned, which is a continuation-in-part of application No. 08/320,157, Oct. 7, 1994, which is a continuation-in-part of application No. 08/160,067, filed as application No. PCT/US94/13930, Nov. 30, 1994, abandoned.

[51] Int. Cl.<sup>6</sup> ..... **C12Q 1/70; A61K 39/245; A61K 39/23**

[52] U.S. Cl. .... **435/5; 424/230.1; 424/233.1**

[58] Field of Search ..... **435/4, 5, 7.1, 69.1, 435/71.1, 172.3; 530/350; 436/501**

## [56] References Cited

### FOREIGN PATENT DOCUMENTS

WO 93/04169 3/1993 WIPO.  
 WO 94/00572 1/1994 WIPO.  
 WO 95/00160 1/1995 WIPO.  
 WO 95/00642 1/1995 WIPO.  
 WO 95/05738 3/1995 WIPO.  
 WO 95/05750 3/1995 WIPO.  
 WO 95/15084 6/1995 WIPO.

### OTHER PUBLICATIONS

Ameisen et al., "Cell dysfunction and depletion in AIDS: The programmed cell death hypothesis" *Immunol. Today* (1991) 12: 102-105.

Barr, "Expression of foreign genes in yeast" *Transgenesis* (1992) pp. 55-79.

Boise et al., "bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death" *Cell* (1993) 74: 597-608.

Chen-Levy et al., "The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation" *Mol. Cell Biol.* (1989) 9: 701-710.

Chittenden et al., "Unduction of apoptosis by the Bcl-2 homologue Bak" *Nature* (1995) 347: 733-736.

Clearly et al., "Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation" *Cell* (1986) 47: 19-28.

Cohen et al., "Apoptosis and programmed cell death in immunity" *Annu. Rev. Immunol.* (1992) 10: 267-293.

Duke et al., "IL-2 addiction: Withdrawal of growth factor activates a suicide program in dependent T Cells" *Lymphokine Res.* (1986) 5: 289-299.

Edgington, "Looking death in the eye: Apoptosis and cancer research" *Biotech.* (1993).

Farrow et al., "Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K" *Nature* (1995) 374: 731-733.

Feinberg et al., "A technique for radiolabeling DNA restriction endonuclease to high specific activity" *Anal. Biochem.* (1984) 137: 266-267.

Gerchenson et al., "Apoptosis: A different type of cell death" *FASEB J.* (1992) 6: 2450-2455.

Hickish et al., "Ultrastructural localization of BHRF1: An Epstein-Barr virus gene product which has homology with bcl-2" *Cancer Research* (1994) 54: 2808-2811.

Hockenbery et al., "Bcl-2 functions in an antioxidant pathway to prevent apoptosis" *Cell* (1993) 75: 241-251.

(List continued on next page.)

Primary Examiner—Laurie Scheiner


Assistant Examiner—Jeffrey S. Parkin

Attorney, Agent, or Firm—Sheridan Ross P.C.

## [57] ABSTRACT

The present invention provides methods for screening potential anti-viral therapeutic agents by monitoring their ability to disrupt the interaction between the BAK protein and a viral protein.

6 Claims, 8 Drawing Sheets



1) *In vitro* co-translated proteins  
 2) Proteins bound to anti-FLAG agarose

Under the Paperwork Reduction Act of 1992, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/63 (11-89)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

# REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

RECEIVED  
SEP 14 2000  
File Information Unit

In re Application of

Application Number

08/160,067

Filed

Nov. 30, 1994

Group Art Unit

1642

Examiner

Paper No. 24

Assistant Commissioner for Patents  
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

☒ (A) referred to in United States Patent Number 5,998,131 column 62

☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. \_\_\_\_\_, filed \_\_\_\_\_, on page \_\_\_\_\_ of paper number \_\_\_\_\_

☐ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. \_\_\_\_\_, filed \_\_\_\_\_, or

☐ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Chris Ribey

Signature

Chris Ribey

Typed or printed name

9/14/00

Date

FOR PTO USE ONLY

Approved by: \_\_\_\_\_

(Initials)

Unit: \_\_\_\_\_



US005998131A

**United States Patent** [19]  
**Barr et al.**

[11] **Patent Number:** **5,998,131**  
 [45] **Date of Patent:** **Dec. 7, 1999**

[54] **SCREENING METHODS FOR THE IDENTIFICATION OF COMPOUNDS CAPABLE OF ABROGATING BAK-BHRF-1 PROTEIN INTERACTIONS**

[75] **Inventors:** Philip J. Barr, Berkeley; Michael C. Klefer, Clayton, both of Calif.

[73] **Assignee:** LXR Biotechnology, Inc., Richmond, Calif.

[21] **Appl. No.:** 08/944,530

[22] **Filed:** Oct. 7, 1997

#### Related U.S. Application Data

[62] Continuation of application No. 08/426,529, Apr. 20, 1995, abandoned, which is a continuation-in-part of application No. 08/320,157, Oct. 7, 1994, which is a continuation-in-part of application No. 08/160,067, filed as application No. PCT/US94/13930, Nov. 30, 1994, abandoned.

[51] **Int. Cl.<sup>6</sup>** ..... C12Q 1/70; A61K 39/245; A61K 39/23

[52] **U.S. Cl.** ..... 435/5; 424/230.1; 424/233.1

[58] **Field of Search** ..... 435/4, 5, 7.1, 69.1, 435/71.1, 172.3; 530/350; 436/501

#### [56] References Cited

##### FOREIGN PATENT DOCUMENTS

WO 93/04169 3/1993 WIPO .  
 WO 94/00572 1/1994 WIPO .  
 WO 95/00160 1/1995 WIPO .  
 WO 95/00642 1/1995 WIPO .  
 WO 95/05738 3/1995 WIPO .  
 WO 95/05750 3/1995 WIPO .  
 WO 95/15084 6/1995 WIPO .

##### OTHER PUBLICATIONS

Ameisen et al., "Cell dysfunction and depletion in AIDS: The programmed cell death hypothesis" *Immunol. Today* (1991) 12: 102-105.

Barr, "Expression of foreign genes in yeast" *Transgenesis* (1992) pp. 55-79.

Boise et al., "bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death" *Cell* (1993) 74: 597-608.

Chen-Levy et al., "The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation" *Mol. Cell Biol.* (1989) 9: 701-710.

Chittenden et al., "Unduction of apoptosis by the Bcl-2 homologue Bak" *Nature* (1995) 347: 733-736.

Clearly et al., "Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation" *Cell* (1986) 47: 19-28.

Cohen et al., "Apoptosis and programmed cell death in immunity" *Ann. Rev. Immunol.* (1992) 10: 267-293.

Duke et al., "IL-2 addiction: Withdrawal of growth factor activates a suicide program in dependent T Cells" *Lymphokine Res.* (1986) 5: 289-299.

Edgington, "Looking death in the eye: Apoptosis and cancer research" *Biotech.* (1993).

Farrow et al., "Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K" *Nature* (1995) 374: 731-733.

Feinberg et al., "A technique for radiolabeling DNA restriction endonuclease to high specific activity" *Anal. Biochem.* (1984) 137: 266-267.

Gerchenson et al., "Apoptosis: A different type of cell death" *FASEB J.* (1992) 6: 2450-2455.

Hickish et al., "Ultrastructural localization of BHRF1: An Epstein-Barr virus gene product which has homology with bcl-2" *Cancer Research* (1994) 54: 2808-2811.

Hockenbery et al., "Bcl-2 functions in an antioxidant pathway to prevent apoptosis" *Cell* (1993) 75: 241-251.

(List continued on next page.)

*Primary Examiner*—Laurie Scheiner


*Assistant Examiner*—Jeffrey S. Parkin

*Attorney, Agent, or Firm*—Sheridan Ross P.C.

#### [57] ABSTRACT

The present invention provides methods for screening potential anti-viral therapeutic agents by monitoring their ability to disrupt the interaction between the BAK protein and a viral protein.

6 Claims, 8 Drawing Sheets



1) *In vitro* co-translated proteins  
 2) Proteins bound to anti-FLAG agarose